{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T23:15:53Z","timestamp":1783206953800,"version":"3.54.6"},"reference-count":254,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019125","name":"Sorbonne Universite","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018010","name":"National Additive Manufacturing Innovation Cluster","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Government of Singapore Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"La Ligue Contre Le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.114996","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:00:46Z","timestamp":1778108446000},"page":"114996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Is platinum the new gold? Re-evaluating platinum's enduring role and future potential in the era of novel ovarian cancer therapies"],"prefix":"10.1016","volume":"395","author":[{"given":"Andres Pachon","family":"Roa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram Pravin Kumar","family":"Muthuramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Lopez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lih-Wen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene C.","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Adriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Han","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Pastorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114996_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2026.114996_bb0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00432-025-06277-9","article-title":"Global, regional, and national burden of ovarian cancer in women aged 45+from 1990 to 2021 and projections for 2050: a systematic analysis based on the 2021 global burden of disease study","volume":"151","author":"Ren","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0015","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0020","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/GO.21.00085","article-title":"Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline","author":"Vanderpuye","year":"2021","journal-title":"JCO Glob. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ijgo.70282","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2025 update","volume":"171","author":"Renz","year":"2025","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.jconrel.2026.114996_bb0030","first-page":"635","article-title":"Ovarian cancer","volume":"108","author":"Burges","year":"2011","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.jconrel.2026.114996_bb0035","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2026.114996_bb0040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb0045","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","article-title":"Platinum-based drugs: past, present and future","volume":"77","author":"Dilruba","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0050","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jconrel.2026.114996_bb0055","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1517\/13543784.9.6.1373","article-title":"An update on satraplatin: the first orally available platinum anticancer drug","volume":"9","author":"Kelland","year":"2000","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2026.114996_bb0060","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0006-2952(02)00983-8","article-title":"JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin","volume":"63","author":"Fokkema","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0065","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.chembiol.2004.03.024","article-title":"Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes","volume":"11","author":"Barnes","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0070","doi-asserted-by":"crossref","first-page":"8060","DOI":"10.1021\/jm0506468","article-title":"Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake","volume":"48","author":"Ang","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114996_bb0075","doi-asserted-by":"crossref","first-page":"22199","DOI":"10.1073\/pnas.0912276106","article-title":"Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate","volume":"106","author":"Dhar","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb0080","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1039\/C5SC04205D","article-title":"Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action","volume":"7","author":"Raveendran","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb0085","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/bjc.1998.710","article-title":"Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials","volume":"78","author":"Aabo","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb0090","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1023\/A:1012259625746","article-title":"Current and future potential roles of the platinum drugs in the treatment of ovarian cancer","volume":"12","author":"Piccart","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0095","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S0923-7534(20)31491-5","article-title":"Advanced epithelial ovarian cancer: 1998 consensus statements","volume":"10","author":"Berek","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0100","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.hoc.2018.07.010","article-title":"Diagnosis and treatment of ovarian cancer","volume":"32","author":"Orr","year":"2018","journal-title":"Hematol. Oncol. Clin."},{"key":"10.1016\/j.jconrel.2026.114996_bb0105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/JEP.S267383","article-title":"Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy","volume":"13","author":"Tchounwou","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0110","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.nbd.2010.11.017","article-title":"Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons","volume":"41","author":"Podratz","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2026.114996_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225650","article-title":"Microtubule targeting agents in disease: classic drugs, novel roles","volume":"13","author":"Wordeman","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.114996_bb0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jnci\/95.2.105","article-title":"International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma","volume":"95","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2026.114996_bb0125","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.ccr.2009.01.028","article-title":"Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA","volume":"253","author":"Arnesano","year":"2009","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.114996_bb0130","series-title":"Comprehensive Medicinal Chemistry II","first-page":"129","article-title":"7.06 - alkylating and platinum antitumor compounds","author":"Hubbard","year":"2007"},{"key":"10.1016\/j.jconrel.2026.114996_bb0135","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of Cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"key":"10.1016\/j.jconrel.2026.114996_bb0140","doi-asserted-by":"crossref","first-page":"F835","DOI":"10.1152\/ajprenal.00285.2017","article-title":"Developing better mouse models to study cisplatin-induced kidney injury","volume":"313","author":"Sharp","year":"2017","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0093-7754(03)00399-3","article-title":"Oxaliplatin-safety profile: neurotoxicity","volume":"30","author":"Grothey","year":"2003","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","article-title":"Cisplatin resistance and opportunities for precision medicine","volume":"106","author":"Amable","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb0155","first-page":"1459","article-title":"cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice","volume":"63","author":"Schabel","year":"1979","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.jconrel.2026.114996_bb0160","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/annonc\/mdx229","article-title":"Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy","volume":"28","author":"Roncolato","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0165","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/IGC.0000000000001182","article-title":"Predicting 6- and 12-month risk of mortality in patients with platinum-resistant advanced-stage ovarian cancer: prognostic model to guide palliative care referrals","volume":"28","author":"Foote","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb0170","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/IGC.0000000000001222","article-title":"Treatment patterns and health outcomes in platinum-refractory or platinum-resistant ovarian Cancer: A retrospective medical record review","volume":"28","author":"Parikh","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (review)","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2026.114996_bb0180","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/cancers11010119","article-title":"Platinum resistance in ovarian cancer: role of DNA repair","volume":"11","author":"Damia","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.114996_bb0185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb0190","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.3390\/ijms20174136","article-title":"New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment","volume":"20","author":"Chen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb0195","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.120066","article-title":"Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?","author":"Borst","year":"2012","journal-title":"Open Biol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0200","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.semcancer.2020.12.024","article-title":"Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer","volume":"77","author":"Ghoneum","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0205","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2353\/ajpath.2007.060903","article-title":"Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer","volume":"170","author":"Said","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0210","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/ijc.32854","article-title":"Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1\/Akt signaling pathway","volume":"146","author":"Yoshihara","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb0215","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.1008585","article-title":"Cell-intrinsic and tumor microenvironmental determinants of platinum resistance in epithelial ovarian cancer","author":"Chen","year":"2026","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0220","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.2147\/CMAR.S179189","article-title":"IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis","volume":"10","author":"Browning","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb0225","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/15592294.2020.1853402","article-title":"Methylomic signatures of high grade serous ovarian cancer","volume":"16","author":"Cardenas","year":"2021","journal-title":"Epigenetics"},{"key":"10.1016\/j.jconrel.2026.114996_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103327","article-title":"Tumor hypoxia: the major culprit behind cisplatin resistance in cancer patients","volume":"162","author":"Devarajan","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0235","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1186\/s12885-015-1539-8","article-title":"Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer","volume":"15","author":"McEvoy","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb0240","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Ruffell","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.114996_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109539","article-title":"GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma","volume":"68","author":"El-Arabey","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jconrel.2026.114996_bb0250","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1073\/pnas.1106645108","article-title":"Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem\/initiating cells","volume":"108","author":"Jinushi","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb0255","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/1097-0142(19901015)60:8+<2075::AID-CNCR2820601521>3.0.CO;2-F","article-title":"Multidrug resistance in ovarian cancer","volume":"60","author":"Fojo","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb0260","article-title":"Bevacizumab and ovarian cancer","author":"Garcia","year":"2012","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0265","doi-asserted-by":"crossref","first-page":"12389","DOI":"10.18632\/oncotarget.13310","article-title":"Bevacizumab in ovarian cancer: a critical review of phase III studies","volume":"8","author":"Rossi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2026.114996_bb0270","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114996_bb0275","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/cei.13255","article-title":"Immunotherapies based on PD-1\/PD-L1 pathway inhibitors in ovarian cancer treatment","volume":"195","author":"Paw\u0142owska","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0280","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252665","article-title":"Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer","volume":"16","author":"Walsh","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2026.114996_bb0290","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1200\/jco.2015.33.15_suppl.5510","article-title":"Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study","volume":"33","author":"Varga","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0295","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","article-title":"Mirvetuximab Soravtansine: First Approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2026.114996_bb0300","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/ijgc-2023-004924","article-title":"Mirvetuximab soravtansine-gynx: first antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer","volume":"34","author":"Bogani","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb0305","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D\u2019Andrea","year":"2018","journal-title":"DNA Repair"},{"key":"10.1016\/j.jconrel.2026.114996_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.12.002","article-title":"PARP inhibitors in ovarian cancer","volume":"73","author":"Franzese","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2026.114996_bb0315","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.114996_bb0320","first-page":"7","article-title":"Antiangiogenic therapy for cancer: current and emerging concepts","volume":"19","author":"Jain","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jconrel.2026.114996_bb0325","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/01.ogx.0000452705.82050.e4","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"69","author":"Pujade-Lauraine","year":"2014","journal-title":"Obstet. Gynecol. Surv."},{"key":"10.1016\/j.jconrel.2026.114996_bb0330","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian Cancer","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0335","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ygyno.2010.02.021","article-title":"Bevacizumab toxicities and their management in ovarian cancer","volume":"117","author":"Randall","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0340","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of Cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol.: Mech. Dis."},{"key":"10.1016\/j.jconrel.2026.114996_bb0345","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0350","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0355","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ni0702-611","article-title":"CTLA-4: new insights into its biological function and use in tumor immunotherapy","volume":"3","author":"Egen","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0360","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1\u2013positive advanced ovarian cancer: analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0365","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0370","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of Nivolumab versus Nivolumab and Ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16142545","article-title":"Antibody-drug conjugates: the new treatment approaches for ovarian cancer","volume":"16","author":"Sato","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.114996_bb0380","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","article-title":"Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer","volume":"151","author":"Moore","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0385","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2217\/fon-2017-0646","article-title":"FORWARD I: A phase III study of Mirvetuximab Soravtansine versus chemotherapy in platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0390","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O\u2019Malley","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0395","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","article-title":"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)\u2013targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer","volume":"185","author":"Richardson","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0400","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb0405","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1758834017714993","article-title":"BRCA mutation in ovarian cancer: testing, implications and treatment considerations","volume":"9","author":"Neff","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241511890","article-title":"An overview of PARP resistance in ovarian cancer from a molecular and clinical perspective","volume":"24","author":"Cordani","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb0415","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061607","article-title":"Overcoming platinum and PARP-inhibitor resistance in ovarian cancer","volume":"12","author":"McMullen","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.114996_bb0420","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2015.08.013","article-title":"PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis","volume":"139","author":"Smith","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0425","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jconrel.2023.08.035","article-title":"Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy","volume":"361","author":"Zheng","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114996_bb0430","series-title":"Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy","first-page":"391","article-title":"Ammine\/amine platinum IV Dicarboxylates: A novel class of complexes which circumvent intrinsic cisplatin resistance","author":"Harrap","year":"1991"},{"key":"10.1016\/j.jconrel.2026.114996_bb0435","first-page":"877","article-title":"Satraplatin in the treatment of hormone-refractory metastatic prostate cancer","volume":"3","author":"Armstrong","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jconrel.2026.114996_bb0440","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/13543780903362437","article-title":"Satraplatin: leading the new generation of oral platinum agents","volume":"18","author":"Bhargava","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2026.114996_bb0445","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1200\/JCO.2008.20.1228","article-title":"Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial","volume":"27","author":"Sternberg","year":"2009","journal-title":"JCO"},{"key":"10.1016\/j.jconrel.2026.114996_bb0450","series-title":"Satraplatin: What is it and is it FDA Approved?","year":"2026"},{"key":"10.1016\/j.jconrel.2026.114996_bb0455","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1021\/jm030858+","article-title":"Platinum(IV) complex with Adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines","volume":"47","author":"\u017d\u00e1k","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114996_bb0460","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1124\/mol.106.027730","article-title":"Molecular aspects of antitumor effects of a new platinum(IV) drug","volume":"70","author":"Kasp\u00e1rkov\u00e1","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0465","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jinorgbio.2007.12.015","article-title":"Cytotoxicity, mutagenicity, cellular uptake, DNA and glutathione interactions of lipophilic trans-platinum complexes tethered to 1-adamantylamine","volume":"102","author":"Hal\u00e1mikov\u00e1","year":"2008","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jconrel.2026.114996_bb0470","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","article-title":"The role of glutathione-S-transferase in anti-cancer drug resistance","volume":"22","author":"Townsend","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2026.114996_bb0475","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10715769900301121","article-title":"Overexpression of glutathione S-transferase \u03c0 enhances the adduct formation of cisplatin with glutathione in human cancer cells","volume":"31","author":"Goto","year":"1999","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb0480","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/00001813-200507000-00010","article-title":"Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12","volume":"16","author":"Sova","year":"2005","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2026.114996_bb0485","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00001813-200602000-00012","article-title":"Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts","volume":"17","author":"Sova","year":"2006","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2026.114996_bb0490","series-title":"The State-of-Play and Future of Platinum Drugs 2015","author":"Apps","year":"2026"},{"key":"10.1016\/j.jconrel.2026.114996_bb0495","first-page":"997","article-title":"Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane","volume":"70","author":"Anderson","year":"1986","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.jconrel.2026.114996_bb0500","first-page":"1745","article-title":"Therapeutic and pharmacological studies of Tetrachloro(d,l-trans)1,2-diaminocyclohexane Platinum (IV) (Tetraplatin), a new platinum analogue","volume":"48","author":"Rahman","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb0505","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0272-0590(88)90251-5","article-title":"In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat","volume":"10","author":"Smith","year":"1988","journal-title":"Fundam. Appl. Toxicol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0510","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1006223100561","article-title":"Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812)","volume":"17","author":"Tutsch","year":"1999","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.jconrel.2026.114996_bb0515","first-page":"709","article-title":"Phase I and pharmacokinetic study of Ormaplatin (Tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule","volume":"54","author":"Schilder","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb0520","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/00001813-199410000-00002","article-title":"Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812)","volume":"5","author":"O\u2019Rourke","year":"1994","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2026.114996_bb0525","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0305-7372(85)90015-5","article-title":"Preclinical studies identifying carboplatin as a viable cisplatin alternative","volume":"12","author":"Harrap","year":"1985","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2026.114996_bb0530","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5935\/0101-2800.20130052","article-title":"Acute nephrotoxicity of cisplatin: molecular mechanisms","volume":"35","author":"Peres","year":"2013","journal-title":"Braz. J. Nephrol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0535","first-page":"795","article-title":"Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP)","volume":"67","author":"Creaven","year":"1983","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.jconrel.2026.114996_bb0540","first-page":"409","article-title":"Activity of JM9 in advanced ovarian cancer: a phase I-II trial","volume":"69","author":"Bramwell","year":"1985","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.jconrel.2026.114996_bb0545","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/oxfordjournals.annonc.a057796","article-title":"Original article: five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma","volume":"1","author":"Gurney","year":"1990","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0550","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/0277-5379(88)90338-0","article-title":"Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer","volume":"24","author":"Anderson","year":"1988","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0555","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1002\/anie.201903112","article-title":"Dual-targeting dual-action platinum(IV) platform for enhanced anticancer activity and reduced nephrotoxicity","volume":"58","author":"Babak","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2026.114996_bb0560","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400203","article-title":"Fluorescence-guided spatial drug screening in 3D colorectal cancer spheroids","volume":"13","author":"Yau","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.114996_bb0565","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1021\/acs.jmedchem.4c02263","article-title":"Multitargeting Pt(IV) derivatives of cisplatin or Oxaliplatin inhibit tumor growth in mice without inducing neuropathic pain","volume":"68","author":"Babu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114996_bb0570","doi-asserted-by":"crossref","first-page":"16676","DOI":"10.1021\/acs.inorgchem.9b02796","article-title":"Synthesis and cytotoxicity of water-soluble dual- and triple-action Satraplatin derivatives: replacement of equatorial chlorides of Satraplatin by acetates","volume":"58","author":"Karmakar","year":"2019","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jconrel.2026.114996_bb0575","article-title":"A targeted redox-active dual-action Pt(IV)-Mn(II) prodrug displays enhanced in vivo anticancer activity","volume":"n\/a","author":"Lopez-Sanchez","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.114996_bb0580","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41577-023-00894-6","article-title":"The multifunctional protein HMGB1: 50 years of discovery","volume":"23","author":"Tang","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0585","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1073\/pnas.100108697","article-title":"Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin","volume":"97","author":"He","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb0590","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/excr.1998.4052","article-title":"Estrogen treatment induces elevated expression of HMG1 in MCF-7 cells","volume":"241","author":"Chau","year":"1998","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb0595","doi-asserted-by":"crossref","first-page":"10394","DOI":"10.1073\/pnas.91.22.10394","article-title":"HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease","volume":"91","author":"Huang","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb0600","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/ja0432618","article-title":"Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance","volume":"127","author":"Ang","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114996_bb0605","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1002\/chem.201100586","article-title":"Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation","volume":"17","author":"Parker","year":"2011","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.jconrel.2026.114996_bb0610","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0167-4838(93)90245-M","article-title":"Interactions of glutathione S-transferase-\u03c0 with ethacrynic acid and its glutathione conjugate","volume":"1164","author":"Awasthi","year":"1993","journal-title":"Biochim. Biophys. Acta Protein Struct. Mol. Enzymol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0615","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/cmdc.201100426","article-title":"Evaluation of Platinum\u2013Ethacrynic Acid Conjugates in the treatment of mesothelioma","volume":"6","author":"Zanellato","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2026.114996_bb0620","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of Cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.114996_bb0625","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1042\/BST20160094","article-title":"The Warburg effect: 80 years on","volume":"44","author":"Potter","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jconrel.2026.114996_bb0630","doi-asserted-by":"crossref","DOI":"10.1186\/1743-7075-11-10","article-title":"The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility","volume":"11","author":"Zhang","year":"2014","journal-title":"Nutr. Metab. (Lond.)"},{"key":"10.1016\/j.jconrel.2026.114996_bb0635","article-title":"Pyruvate dehydrogenase kinases (PDKs): an overview toward clinical applications","volume":"41","author":"Wang","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jconrel.2026.114996_bb0640","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/mp200571k","article-title":"Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction","volume":"9","author":"Xue","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.114996_bb0645","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone deacetylase inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114996_bb0650","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","article-title":"Histone deacetylase inhibitors: overview and perspectives","volume":"5","author":"Dokmanovic","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb0655","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2026.114996_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2020.111125","article-title":"Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780\/A2780cis cells","volume":"210","author":"Almotairy","year":"2020","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jconrel.2026.114996_bb0665","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1021\/acs.inorgchem.0c00445","article-title":"Multiaction Pt(IV) carbamate complexes can Codeliver Pt(II) drugs and amine containing bioactive molecules","volume":"59","author":"Babu","year":"2020","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jconrel.2026.114996_bb0670","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/ejic.201601278","article-title":"Platinum(IV) prodrugs \u2013 A step closer to Ehrlich\u2019s vision?","volume":"2017","author":"Kenny","year":"2017","journal-title":"Eur. J. Inorg. Chem."},{"key":"10.1016\/j.jconrel.2026.114996_bb0675","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s10637-024-01479-3","article-title":"Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models","volume":"42","author":"Begum","year":"2024","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.jconrel.2026.114996_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2020.111353","article-title":"Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?","volume":"217","author":"Gibson","year":"2021","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jconrel.2026.114996_bb0685","article-title":"Recent progress in stimuli-activable metallo-prodrugs for cancer therapy","volume":"2","author":"Liang","year":"2024","journal-title":"Smart Mol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0690","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1039\/C7SC01109A","article-title":"Riboflavin as a bioorthogonal photocatalyst for the activation of a Pt IV prodrug","volume":"8","author":"Castro","year":"2017","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb0695","article-title":"An ultrasound-activatable platinum prodrug for sono-sensitized chemotherapy","volume":"9","author":"Liu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.114996_bb0700","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acscentsci.4c01369","article-title":"Targeted radionuclide therapy activates prodrugs for treating metastasis","volume":"10","author":"Guo","year":"2024","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020607","article-title":"Pt(II)-PLGA hybrid in a pH-responsive nanoparticle system targeting ovarian cancer","volume":"15","author":"Wlodarczyk","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114996_bb0710","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2020.06.005","article-title":"Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo","volume":"326","author":"Luo","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114996_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2022.100134","article-title":"Nano-based drug delivery systems: conventional drug delivery routes, recent developments and future prospects","volume":"15","author":"Sultana","year":"2022","journal-title":"Med. Drug Discovery"},{"key":"10.1016\/j.jconrel.2026.114996_bb0720","doi-asserted-by":"crossref","first-page":"18848","DOI":"10.1039\/C5NR05264E","article-title":"Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles","volume":"7","author":"Kang","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2026.114996_bb0725","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s40820-020-00482-6","article-title":"A review on nano-based drug delivery system for cancer chemoimmunotherapy","volume":"12","author":"Mu","year":"2020","journal-title":"Nano-Micro Lett."},{"key":"10.1016\/j.jconrel.2026.114996_bb0730","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.114996_bb0735","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1039\/C5BM00039D","article-title":"Polymeric biomaterials for the delivery of platinum-based anticancer drugs","volume":"3","author":"Kim","year":"2015","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb0740","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1021\/acs.molpharmaceut.7b00466","article-title":"Tobacco mosaic virus-delivered cisplatin restores efficacy in platinum-resistant ovarian cancer cells","volume":"15","author":"Franke","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.114996_bb0745","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.addr.2013.09.014","article-title":"Nanocarriers for delivery of platinum anticancer drugs","volume":"65","author":"Oberoi","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114996_bb0750","doi-asserted-by":"crossref","first-page":"37383","DOI":"10.1021\/acsami.5c07366","article-title":"The Nanocarrier landscapeevaluating key drug delivery vehicles and their capabilities: a translational perspective","volume":"17","author":"Khalid-Salako","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2026.114996_bb0755","doi-asserted-by":"crossref","first-page":"13039","DOI":"10.2147\/IJN.S554821","article-title":"Bridging the gap: the role of advanced formulation strategies in the clinical translation of nanoparticle-based drug delivery systems","volume":"20","author":"Herdiana","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114996_bb0760","article-title":"Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues","volume":"6","author":"Madaan","year":"2014","journal-title":"J. Pharm. Bioallied Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb0765","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1039\/c3tb20724b","article-title":"Dendrimer-based nanodevices for targeted drug delivery applications","volume":"1","author":"Zhu","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2026.114996_bb0770","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.procbio.2023.12.020","article-title":"Revamping precision treatment with nanoparticles envisaging effective drug delivery systems for ovarian cancer","volume":"138","author":"Sharma","year":"2024","journal-title":"Process Biochem."},{"key":"10.1016\/j.jconrel.2026.114996_bb0775","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1007\/s11356-014-3994-1","article-title":"Impact of nanoparticles on human and environment: review of toxicity factors, exposures, control strategies, and future prospects","volume":"22","author":"Sajid","year":"2015","journal-title":"Environ. Sci. Pollut. Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb0780","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201606134","article-title":"Metal\u2013organic framework (MOF)-based drug\/cargo delivery and cancer therapy","volume":"29","author":"Wu","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114996_bb0785","doi-asserted-by":"crossref","first-page":"19627","DOI":"10.1021\/acsomega.4c01437","article-title":"Metal\u2013organic frameworks for cisplatin delivery to cancer cells: a molecular dynamics simulation","volume":"9","author":"Mashayekh","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.jconrel.2026.114996_bb0790","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/1061186X.2021.1949600","article-title":"New generation of viral nanoparticles for targeted drug delivery in cancer therapy","volume":"30","author":"Alvandi","year":"2022","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2026.114996_bb0795","first-page":"897","article-title":"Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT","volume":"31","author":"Yellepeddi","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb0800","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25173982","article-title":"Applications and limitations of dendrimers in biomedicine","volume":"25","author":"Chis","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.114996_bb0805","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s11051-013-1897-6","article-title":"Poly(amido)amine (PAMAM) dendrimer\u2013cisplatin complexes for chemotherapy of cisplatin-resistant ovarian cancer cells","volume":"15","author":"Yellepeddi","year":"2013","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb0810","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051515","article-title":"Combination of drug delivery properties of PAMAM dendrimers and cytotoxicity of platinum(IV) complexes\u2014a more selective anticancer treatment?","volume":"15","author":"Lerchbammer-Kreith","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114996_bb0815","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/nano11041048","article-title":"Polymeric nanoparticle delivery of combination therapy with synergistic effects in ovarian cancer","volume":"11","author":"Levit","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.jconrel.2026.114996_bb0820","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.colsurfb.2019.03.011","article-title":"Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy","volume":"178","author":"Dom\u00ednguez-R\u00edos","year":"2019","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2026.114996_bb0825","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2026.114996_bb0830","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2026.114996_bb0835","doi-asserted-by":"crossref","first-page":"17536","DOI":"10.1039\/C5CC07853A","article-title":"Oral delivery of a platinum anticancer drug using lipid assisted polymeric nanoparticles","volume":"51","author":"Cheng","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2026.114996_bb0840","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s11671-023-03943-0","article-title":"Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review","volume":"18","author":"Unnikrishnan","year":"2023","journal-title":"Discover Nano"},{"key":"10.1016\/j.jconrel.2026.114996_bb0845","doi-asserted-by":"crossref","DOI":"10.3390\/nano15151200","article-title":"Applications of nanoparticles in the diagnosis and treatment of ovarian cancer","volume":"15","author":"El-Mallul","year":"2025","journal-title":"Nanomaterials"},{"key":"10.1016\/j.jconrel.2026.114996_bb0850","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1039\/D0NA00286K","article-title":"Role of inorganic nanoparticle degradation in cancer therapy","volume":"2","author":"Maksoudian","year":"2020","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.jconrel.2026.114996_bb0855","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.nano.2018.01.021","article-title":"Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound","volume":"14","author":"Coluccia","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114996_bb0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112463","article-title":"Bimetallic gold-platinum nanoparticles as a drug delivery system coated with a new drug to target glioblastoma","volume":"214","author":"Stavropoulou","year":"2022","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2026.114996_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2019.115333","article-title":"Synthesis of chitosan-grafted-poly(N-vinylcaprolactam) coated on the thiolated gold nanoparticles surface for controlled release of cisplatin","volume":"227","author":"Banihashem","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2026.114996_bb0870","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12030232","article-title":"Metal organic frameworks as drug targeting delivery vehicles in the treatment of cancer","volume":"12","author":"Cai","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114996_bb0875","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1021\/ja4098862","article-title":"Nanoscale metal\u2013organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells","volume":"136","author":"He","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114996_bb0880","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s12088-024-01367-7","article-title":"Carbon nanotubes in the diagnosis and treatment of ovarian cancer","volume":"65","author":"Chattaraj","year":"2025","journal-title":"Indian J. Microbiol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2020.101811","article-title":"Smart carbon nanotubes for drug delivery system: A comprehensive study","volume":"58","author":"Jha","year":"2020","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114996_bb0890","doi-asserted-by":"crossref","DOI":"10.1039\/D1NA00293G","article-title":"Functionalized carbon nanotubes: synthesis, properties and applications in water purification, drug delivery, and material and biomedical sciences","author":"Dubey","year":"2021","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.jconrel.2026.114996_bb0895","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.biomaterials.2013.09.036","article-title":"Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin","volume":"35","author":"Yoong","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.114996_bb0900","doi-asserted-by":"crossref","first-page":"10179","DOI":"10.2147\/IJN.S220087","article-title":"Toxicity of carbon nanotubes as anti-tumor drug carriers","volume":"14","author":"Yan","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114996_bb0905","doi-asserted-by":"crossref","first-page":"11467","DOI":"10.1021\/ja803036e","article-title":"Targeted Single Wall carbon nanotube mediated Pt(IV) prodrug delivery using folate as a homing device","volume":"130","author":"Dhar","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114996_bb0910","doi-asserted-by":"crossref","first-page":"8438","DOI":"10.1021\/ja073231f","article-title":"Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design","volume":"129","author":"Feazell","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114996_bb0915","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.carbon.2011.11.043","article-title":"Carbon nanotube bottles for incorporation, release and enhanced cytotoxic effect of cisplatin","volume":"50","author":"Li","year":"2012","journal-title":"Carbon"},{"key":"10.1016\/j.jconrel.2026.114996_bb0920","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/1061186X.2023.2193358","article-title":"Virus-like particle-based nanocarriers as an emerging platform for drug delivery","volume":"31","author":"Yuan","year":"2023","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2026.114996_bb0925","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1021\/acs.molpharmaceut.0c00834","article-title":"Cisplatin prodrug-loaded nanoparticles based on Physalis mottle virus for cancer therapy","volume":"17","author":"Hu","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.114996_bb0930","doi-asserted-by":"crossref","first-page":"FSO401","DOI":"10.2144\/fsoa-2019-0001","article-title":"Future of cancer immunotherapy using plant virus-based nanoparticles","volume":"5","author":"Shoeb","year":"2019","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.jconrel.2026.114996_bb0935","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1021\/acs.biomac.2c00831","article-title":"Cisplatin-loaded tobacco mosaic virus for ovarian cancer treatment","volume":"23","author":"Zhao","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2026.114996_bb0940","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1021\/acsnano.5b07360","article-title":"Tobacco mosaic virus delivery of Phenanthriplatin for Cancer therapy","volume":"10","author":"Czapar","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114996_bb0945","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/cancers10070238","article-title":"Micelles structure development as a strategy to improve smart cancer therapy","volume":"10","author":"Hanafy","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.114996_bb0950","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1208\/s12249-014-0113-z","article-title":"Polymeric micelles: Nanocarriers for Cancer-targeted drug delivery","volume":"15","author":"Zhang","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2026.114996_bb0955","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1021\/nn5070259","article-title":"Systemic targeting of lymph node metastasis through the blood vascular system by using size-controlled Nanocarriers","volume":"9","author":"Cabral","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114996_bb0960","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1072-7515(03)00234-5","article-title":"Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications","volume":"197","author":"Morice","year":"2003","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.jconrel.2026.114996_bb0965","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3892\/etm.2016.3134","article-title":"Human lymphatic endothelial cells contribute to epithelial ovarian carcinoma metastasis by promoting lymphangiogenesis and tumour cell invasion","volume":"11","author":"Xie","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.jconrel.2026.114996_bb0970","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/bjc.2011.6","article-title":"A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours","volume":"104","author":"Plummer","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb0975","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-17-1114","article-title":"Phase Ib\/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine in patients with advanced solid tumors","volume":"24","author":"Subbiah","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb0980","doi-asserted-by":"crossref","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2026.114996_bb0985","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114996_bb0990","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.587997","article-title":"Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects","volume":"7","author":"Scioli Montoto","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.jconrel.2026.114996_bb0995","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10040191","article-title":"Solid lipid nanoparticles: emerging colloidal nano drug delivery systems","volume":"10","author":"Mishra","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114996_bb1000","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0939-6411(97)00150-1","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery \u2013 drug release and release mechanism","volume":"45","author":"zur M\u00fchlen","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.114996_bb1005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020559","article-title":"Enhanced efficacy of PEGylated liposomal cisplatin: in vitro and in vivo evaluation","volume":"21","author":"Ghaferi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jallcom.2020.155118","article-title":"Wet chemical mediated hematite \u03b1-Fe2O3 nanoparticles synthesis: preparation, characterization and anticancer activity against human metastatic ovarian cancer","volume":"834","author":"Ramalingam","year":"2020","journal-title":"J. Alloys Compd."},{"key":"10.1016\/j.jconrel.2026.114996_bb1015","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1039\/c2sc01086k","article-title":"Platinum(IV) prodrugs entrapped within multiwalled carbon nanotubes: selective release by chemical reduction and hydrophobicity reversal","volume":"3","author":"Li","year":"2012","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb1020","article-title":"Cisplatin and paclitaxel co-delivery nanosystem for ovarian cancer chemotherapy","volume":"8","author":"Wang","year":"2021","journal-title":"Regener. Biomater."},{"key":"10.1016\/j.jconrel.2026.114996_bb1025","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/03639045.2021.1989451","article-title":"Preparation, characterization and in vitro evaluation of cisplatin-bound triblock polymeric micelle solution for ovarian cancer treatment","volume":"47","author":"Ak","year":"2021","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2026.114996_bb1030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/02652048.2022.2109218","article-title":"Antitumour effects of a solid lipid nanoparticle loaded with gemcitabine and oxaliplatin on the viability, apoptosis, autophagy, and Hsp90 of ovarian cancer cells","volume":"39","author":"Al-Mutairi","year":"2022","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2026.114996_bb1035","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.cclet.2021.10.077","article-title":"Integrating of lipophilic platinum(IV) prodrug into liposomes for cancer therapy on patient-derived xenograft model","volume":"33","author":"Li","year":"2022","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.jconrel.2026.114996_bb1040","doi-asserted-by":"crossref","DOI":"10.3390\/biom12060784","article-title":"Nano-based approved pharmaceuticals for cancer treatment: present and future challenges","volume":"12","author":"Rodr\u00edguez","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2026.114996_bb1045","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114996_bb1050","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1452","article-title":"Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles","volume":"9","author":"Selby","year":"2017","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.114996_bb1055","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.addr.2009.06.004","article-title":"ProLindac\u2122 (AP5346): A review of the development of an HPMA DACH platinum polymer therapeutic","volume":"61","author":"Nowotnik","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114996_bb1060","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00280-006-0397-0","article-title":"Phase I and pharmacokinetic trial of AP5346, a DACH\u2013platinum\u2013polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients","volume":"60","author":"Campone","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114996_bb1065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/157340711795163794","article-title":"AP5346 (ProLindac\u2122), A DACH platinum polymer conjugate in phase II trials against ovarian Cancer","volume":"7","author":"Nowotnik","year":"2011","journal-title":"Curr. Bioact. Compd."},{"key":"10.1016\/j.jconrel.2026.114996_bb1070","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202509094","article-title":"Delivery of antisense oligonucleotides using the nano-cell vesicle technology system (nCVTs) for targeted cancer therapy","volume":"22","author":"Ou","year":"2026","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2026.114996_bb1075","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb1080","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1535-7163.MCT-22-0322","article-title":"Discovery of STRO-002, a novel homogeneous ADC targeting folate receptor alpha, for the treatment of ovarian and endometrial cancers","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.114996_bb1085","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.687322","article-title":"CD44v6-O-MWNTS-loaded gemcitabine and CXCR4 siRNA improves the anti-tumor effectiveness of ovarian cancer","author":"Yin","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2026.114996_bb1090","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/pharmaceutics11100543","article-title":"Active cellular and subcellular targeting of nanoparticles for drug delivery","volume":"11","author":"Nag","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114996_bb1095","doi-asserted-by":"crossref","first-page":"9123","DOI":"10.3390\/ijms21239123","article-title":"Aptamer-functionalized nanoparticles in targeted delivery and Cancer therapy","volume":"21","author":"Fu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb1100","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/1061186X.2018.1491978","article-title":"Targeted cancer drug delivery with aptamer-functionalized polymeric nanoparticles","volume":"27","author":"Zununi Vahed","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2026.114996_bb1105","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.2217\/nnm-2018-0205","article-title":"AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells","volume":"13","author":"Vandghanooni","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114996_bb1110","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/IJN.S152474","article-title":"Pharmacokinetics and in vitro\/in vivo antitumor efficacy of aptamer-targeted Ecoflex\u00ae nanoparticles for docetaxel delivery in ovarian cancer","volume":"13","author":"Ghassami","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114996_bb1115","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.nano.2016.11.015","article-title":"RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery","volume":"13","author":"Pi","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114996_bb1120","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1002\/anie.202005309","article-title":"Molecularly imprinted polymer nanoparticles: an emerging versatile platform for cancer therapy","volume":"60","author":"Xu","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2026.114996_bb1125","doi-asserted-by":"crossref","DOI":"10.1016\/j.hybadv.2022.100001","article-title":"Exploring molecularly imprinted polymers as artificial antibodies for efficient diagnostics and commercialization: a critical overview","volume":"1","author":"Dixit","year":"2022","journal-title":"Hybrid Adv."},{"key":"10.1016\/j.jconrel.2026.114996_bb1130","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1021\/acs.chemrev.0c00428","article-title":"Molecularly imprinted polymers: antibody mimics for bioimaging and therapy","volume":"120","author":"Haupt","year":"2020","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.114996_bb1135","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40273-015-0304-9","article-title":"Cost effectiveness of chemotherapeutic agents and targeted biologics in ovarian cancer: a systematic review","volume":"33","author":"Poonawalla","year":"2015","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jconrel.2026.114996_bb1140","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(24)00550-6","article-title":"Global fertility in 204 countries and territories, 1950\u20132021, with forecasts to 2100: a comprehensive demographic analysis for the global burden of disease study 2021","volume":"403","author":"Bhattacharjee","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.114996_bb1145","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123090","article-title":"Nano-polymeric platinum activates PAR2 gene editing to suppress tumor metastasis","volume":"317","author":"Jiang","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.114996_bb1150","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.1021\/acsnano.1c00698","article-title":"Tailoring supramolecular prodrug nanoassemblies for reactive nitrogen species-potentiated chemotherapy of liver cancer","volume":"15","author":"Deng","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114996_bb1155","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1021\/jacs.5c03831","article-title":"Boosting cancer cell Ferroptosis with carbon monoxide poisoned hemoglobin","volume":"147","author":"Wang","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114996_bb1160","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202004766","article-title":"Fighting against drug-resistant tumors using a dual-responsive Pt(IV)\/Ru(II) bimetallic polymer","volume":"32","author":"Zeng","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114996_bb1165","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.apsb.2023.11.028","article-title":"Bimetallic nanoparticles as cascade sensitizing amplifiers for low-dose and robust cancer radio-immunotherapy","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.114996_bb1170","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1021\/acsnano.4c15115","article-title":"Platinum(IV)-backboned polymer prodrug-functionalized manganese oxide nanoparticles for enhanced lung Cancer Chemoimmunotherapy via amplifying stimulator of interferon genes activation","volume":"19","author":"Liu","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114996_bb1175","article-title":"Glucose metabolism-targeted poly(amino acid) nanoformulation of Oxaliplatin(IV)-aspirin prodrug for enhanced chemo-immunotherapy","volume":"37","author":"Yang","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114996_bb1180","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1021\/nn404501g","article-title":"Facing the truth about nanotechnology in drug delivery","volume":"7","author":"Park","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114996_bb1185","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1021\/acsnano.9b08142","article-title":"Meta-analysis of nanoparticle delivery to tumors using a physiologically based pharmacokinetic modeling and simulation approach","volume":"14","author":"Cheng","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114996_bb1190","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/wnan.143","article-title":"Overcoming in vivo barriers to targeted nanodelivery","volume":"3","author":"Chrastina","year":"2011","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.114996_bb1195","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jconrel.2018.01.009","article-title":"Nanotherapeutics in oral and parenteral drug delivery: key learnings and future outlooks as we think small","volume":"272","author":"Tyagi","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114996_bb1200","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114996_bb1205","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12885-016-2385-z","article-title":"HERMIONE: a randomized phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician\u2019s choice plus trastuzumab in patients with previously treated, anthracycline-na\u00efve, HER2-positive, locally advanced\/metastatic breast cancer","volume":"16","author":"Miller","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2026.114996_bb1210","author":"Inc MP"},{"key":"10.1016\/j.jconrel.2026.114996_bb1215","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdh092","article-title":"Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer","volume":"15","author":"Matsumura","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb1220","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaoncol.2018.2168","article-title":"Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate Cancer: a phase 2 clinical trial","volume":"4","author":"Autio","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jconrel.2026.114996_bb1225","doi-asserted-by":"crossref","first-page":"11449","DOI":"10.1073\/pnas.1411393111","article-title":"Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA","volume":"111","author":"Zuckerman","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.114996_bb1230","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40580-021-00282-7","article-title":"Cancer nanotechnology: current status and perspectives","volume":"8","author":"Kemp","year":"2021","journal-title":"Nano Convergence"},{"key":"10.1016\/j.jconrel.2026.114996_bb1235","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.2147\/IJN.S497510","article-title":"Overcoming biological barriers in cancer therapy: cell membrane-based nanocarrier strategies for precision delivery","volume":"20","author":"Li","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114996_bb1240","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1039\/C7NR08720A","article-title":"nCVTs: a hybrid smart tumour targeting platform","volume":"10","author":"Goh","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2026.114996_bb1245","doi-asserted-by":"crossref","first-page":"24035","DOI":"10.1039\/D5NR02316E","article-title":"Nano-biohybrid systems for the targeted delivery of chemotherapeutics","volume":"17","author":"Hsuan Ou","year":"2025","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2026.114996_bb1250","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","article-title":"Current hurdles to the translation of nanomedicines from bench to the clinic","volume":"12","author":"\u0110or\u0111evi\u0107","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb1255","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1007\/s13346-024-01646-2","article-title":"Toward an international standardisation roadmap for nanomedicine","volume":"14","author":"Caputo","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb1260","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","article-title":"Survey of clinical translation of Cancer nanomedicines\u2014lessons learned from successes and failures","volume":"52","author":"He","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb1265","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13346-020-00740-5","article-title":"Challenges in nanomedicine clinical translation","volume":"10","author":"Metselaar","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.114996_bb1270","series-title":"Ovarian cancer (Version 3.2025)","author":"National Comprehensive Cancer Network","year":"2026"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T22:24:41Z","timestamp":1783203881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926003998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":254,"alternative-id":["S0168365926003998"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114996","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is platinum the new gold? Re-evaluating platinum's enduring role and future potential in the era of novel ovarian cancer therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114996"}}